[go: up one dir, main page]

YU65401A - Primena ksenona ili smeša ksenonskog gasa za proizvodnju farmaceutskog preparata za lečenje neurointoksinacija - Google Patents

Primena ksenona ili smeša ksenonskog gasa za proizvodnju farmaceutskog preparata za lečenje neurointoksinacija

Info

Publication number
YU65401A
YU65401A YU65401A YUP65401A YU65401A YU 65401 A YU65401 A YU 65401A YU 65401 A YU65401 A YU 65401A YU P65401 A YUP65401 A YU P65401A YU 65401 A YU65401 A YU 65401A
Authority
YU
Yugoslavia
Prior art keywords
xenon
pharmaceutical preparation
gas mixtures
producing pharmaceutical
neurointoxications
Prior art date
Application number
YU65401A
Other languages
English (en)
Inventor
Christian Petzelt
Wolfgang J. Kox
Original Assignee
Aga Ab.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7900688&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=YU65401(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aga Ab. filed Critical Aga Ab.
Publication of YU65401A publication Critical patent/YU65401A/sh
Publication of RS49756B publication Critical patent/RS49756B/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Inorganic Chemistry (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Pronalazak se odnosi na primenu ksenona ili smeša ksenonskog gasa za proizvodnju farmaceutskog preparata za lečenje neurointoksikacija i to naročito onih prouzrokovanih viškom neurotransmitera. Ksenon može da smanji oslobadjanje neurotransmitera, naročito dopamina, što je prouzrokovano na primer hipoksičnim situacijama kao što su apopleksija ili kraniocerebralna trauma. Preparat koji sadrži ksenon može takodje da se koristi kao terapeutsko sredstvo u slučaju depresije, šizofrenije i Parkinsonove bolesti, u kojima je neurotransmiterski balans takodje poremećen. Primena inhaliranjem je jednostavna i neškodljivost ksenona je već dokazana njegovom upotrebom kao anestetičkog sredstva.
YUP-654/01A 1999-03-11 2000-03-08 Primena ksenona ili smeša ksenonskog gasa za proizvodnju farmaceutskog preparata za lečenje neurointoksikacija RS49756B (sr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19910986A DE19910986C2 (de) 1999-03-11 1999-03-11 Verwendung von Xenon bei der Behandlung von Neurointoxikationen

Publications (2)

Publication Number Publication Date
YU65401A true YU65401A (sh) 2004-07-15
RS49756B RS49756B (sr) 2008-04-04

Family

ID=7900688

Country Status (29)

Country Link
US (3) US6559190B1 (sh)
EP (1) EP1158992B2 (sh)
JP (1) JP4954373B2 (sh)
KR (1) KR100674407B1 (sh)
CN (1) CN1170544C (sh)
AR (1) AR022886A1 (sh)
AT (1) ATE248599T1 (sh)
AU (1) AU757361B2 (sh)
BG (1) BG105889A (sh)
BR (1) BR0010456A (sh)
CA (1) CA2367136C (sh)
CZ (1) CZ302864B6 (sh)
DE (2) DE19910986C2 (sh)
DK (1) DK1158992T3 (sh)
EE (1) EE200100480A (sh)
ES (1) ES2206202T5 (sh)
HK (1) HK1048073B (sh)
HU (1) HUP0201393A3 (sh)
IL (2) IL145177A0 (sh)
MD (1) MD2935C2 (sh)
NO (1) NO20014379L (sh)
PL (1) PL202941B1 (sh)
PT (1) PT1158992E (sh)
RS (1) RS49756B (sh)
RU (1) RU2246949C2 (sh)
SI (1) SI1158992T1 (sh)
SK (1) SK285111B6 (sh)
WO (1) WO2000053192A1 (sh)
ZA (1) ZA200107291B (sh)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9913677D0 (en) 1999-06-11 1999-08-11 Imperial College Formulation
US6653354B2 (en) 1999-07-29 2003-11-25 Protexeon Limited NMDA antagonist comprising xenon
GB9917822D0 (en) * 1999-07-29 1999-09-29 Imperial College Nmda antagonist
DE10045829A1 (de) * 2000-09-14 2002-04-04 Messer Griesheim Gmbh Volatile Anästhesiemittel mit Xenon
DE10054563A1 (de) * 2000-11-03 2002-05-16 Messer Griesheim Gmbh Verfahren und Vorrichtung zur Betonherstellung
US20020102211A1 (en) * 2000-12-07 2002-08-01 Renshaw Perry F. Use of magnetic resonance imaging in diagnosis of membrane fluidity-related disorders
GB0209998D0 (en) * 2002-05-01 2002-06-12 Protexeon Ltd Use
GB0210021D0 (en) * 2002-05-01 2002-06-12 Air Prod & Chem Ultrasonic gas analyser
DK1515732T3 (da) * 2002-06-12 2009-05-11 Air Liquide Deutschland Gmbh Cerebral protektion med en xenonholdig gas
WO2004004782A1 (de) * 2002-07-05 2004-01-15 Messer Griesheim Gmbh Xenon enthaltendes adjuvans
GB0218153D0 (en) * 2002-08-05 2002-09-11 Ic Innovations Ltd An analgesic agent for newborn or retal subjects
US7681572B2 (en) 2002-08-20 2010-03-23 Aga Ab Method and devices for administration of therapeutic gases
US7337776B2 (en) 2002-08-20 2008-03-04 Aga Ab Methods for easing pain and anxiety from atrial or ventricular defibrillation
FR2858233B1 (fr) * 2003-07-30 2008-04-11 Air Liquide Sante Int Medicament gazeux inhalable a base de xenon et de protoxyde d'azote
EP1670489B1 (en) * 2003-10-10 2007-12-12 Protexeon Limited Use of xenon with hypothermia for treating neonatal asphyxia
BRPI0415616A (pt) * 2003-10-21 2006-12-12 Aga Ab uso do xenÈnio para a prevenção da morte programada da célula
FR2863169B1 (fr) * 2003-12-08 2006-02-10 Air Liquide Sante Int Medicament gazeux inhalable a base d'argon pour le traitement des neuro-intoxications
EP1552840A1 (en) * 2004-01-07 2005-07-13 Aga Ab Use of a xenon/carbon monoxide mixture for the protection of cells
US7070005B2 (en) * 2004-02-10 2006-07-04 Planetair Turf Products, Llc Soil aerator assembly
WO2006017524A2 (en) * 2004-08-02 2006-02-16 Olney John W Preventing pathological increases in the rate of nerve cell suicide in immature nervous systems
WO2007075100A1 (en) * 2005-12-27 2007-07-05 Zakrytoe Aktsionernoe Obshchestvo 'atom-Med Center' Method for treating drug dependence
EP1980260A1 (en) * 2007-04-10 2008-10-15 Nicholas Peter Franks Use of hyperbaric conditions to provide neuroprotection
US8435569B2 (en) * 2007-04-30 2013-05-07 Nnoxe Pharmaceutiques Inc. Pharmaceutical composition comprising at least one thrombolytic agent (A) and at least one gas (B) selected from the group consisting of nitrous oxide, argon, xenon, helium, neon
ITMI20071031A1 (it) * 2007-05-22 2008-11-23 Acetilene & Deriv Ati Siad Spa Uso di xenon per la protezione di organi da danno ischemico
WO2010035074A1 (en) * 2008-09-25 2010-04-01 Nnoxe Pharmaceutiques Inc Use of nitrous oxide, argon, xenon, helium, or neon, for the manufacture of a pharmaceutical composition for treating ischemic insults in patients who cannot be treated with thrombolytic agents
FR2952305B1 (fr) * 2009-11-10 2012-04-27 Air Liquide Medicament inhalable a base de xenon pour traiter ou pour prevenir les dyskinesies
WO2011081612A1 (ru) * 2009-12-31 2011-07-07 Bondarenko Vitaliy Leonidovich Применение криптона или ксенона в качестве противовирусного средства
FR2956323B1 (fr) 2010-02-15 2013-12-20 Air Liquide Medicament gazeux inhalable a base d'argon contre les deficiences ou defaillances d'organes peripheriques
FR2960779A1 (fr) 2010-06-08 2011-12-09 Air Liquide Medicament gazeux inhalable a base de krypton contre les deficiences ou defaillances d'organes peripheriques
FR2964036B1 (fr) 2010-08-24 2013-04-12 Air Liquide Medicament gazeux inhalable a base de krypton pour le traitement des neuro-intoxications
JP6103648B2 (ja) * 2011-02-07 2017-03-29 リッチ テクノロジーズ ホールディング カンパニー リミテッド ライアビリティー カンパニー 細胞の保存及び細胞培養のための方法
FR2975597B1 (fr) * 2011-05-24 2013-12-27 Air Liquide Utilisation de neon pour le traitement des neuro-intoxications, notamment des maladies enurodegeneratives et demyelinisantes
WO2013049118A1 (en) 2011-09-26 2013-04-04 Rich Products Corporation Method for living tissue preservation
RU2489154C1 (ru) * 2012-05-31 2013-08-10 Сергей Александрович Наумов Способ лечения вирусных гепатитов
CN110464709A (zh) 2012-08-10 2019-11-19 德克萨斯州大学系统董事会 用于治疗中风的神经保护性脂质体组合物和方法
FR2996457B1 (fr) 2012-10-09 2019-11-29 L'air Liquide,Societe Anonyme Pour L'etude Et L'exploitation Des Procedes Georges Claude Utilisation d'argon pour prevenir ou traiter les consequences neurologiques d'un choc septique
FR2996458B1 (fr) * 2012-10-09 2015-02-27 Air Liquide Utilisation de xenon pour prevenir ou traiter les consequences neurologiques d'un choc septique
FR2996459B1 (fr) * 2012-10-09 2015-02-06 Air Liquide Utilisation d'un melange argon/xenon pour prevenir ou traiter les consequences neurologiques d'un choc septique
EP2931291B1 (en) 2012-12-11 2021-10-20 The McLean Hospital Corporation Xenon treatment as an adjunct to psychotherapy for psychiatric disorders
CA2905155C (en) 2013-03-15 2021-11-16 The Board Of Regents Of The University Of Texas System Liquids rich in noble gas and methods of their preparation and use
FR3007983B1 (fr) * 2013-07-08 2015-06-26 Air Liquide Association de xenon et d'un antagoniste des recepteurs nmda pour lutter contre une maladie neurodegenerative
FR3022456B1 (fr) * 2014-06-20 2016-07-15 Air Liquide Xenon associe a un antagoniste des recepteurs nmda pour lutter contre une proliferation tumorale dans le systeme nerveux central
FR3027226B1 (fr) * 2014-10-17 2017-12-08 L'air Liquide Sa Pour L'etude Et L'exploitation Des Procedes Georges Claude Medicament pour traiter une maladie liee a un dysfonctionnement de la transmission synaptique dopaminergique
EP3313384A4 (en) 2015-06-23 2019-04-03 Nobilis Therapeutics, Inc. THERAPEUTIC IMMUNE MODULATION USING NOBLE GAS COMPOSITIONS
WO2017083373A1 (en) * 2015-11-09 2017-05-18 The Mclean Hospital Corporation Methods and compositions for the prevention of suicide, homicide and self-harming behaviors
US20170341980A1 (en) * 2016-05-31 2017-11-30 Noblis Therapeutics, Inc. Noble gas neuroprotection and neuroregeneration from treatment related neurotoxicity
US10485825B2 (en) * 2016-08-29 2019-11-26 Nobilis Therapeutics, Inc. Prevention of pregnancy complications by noble gas administration
EP3532073A4 (en) * 2016-10-31 2020-09-02 Nobilis Therapeutics, Inc. TREATMENT OF ANXIETY DISORDER AND INCREASED ANTI-ANXIETY INTERVENTIONS BY ADMINISTRATION OF MIXTURES CONTAINING A NOBLE GAS
CN107569509B (zh) * 2017-02-22 2018-09-21 滨州医学院 氙或氙气体混合物在制备治疗癫痫的制剂中的用途
CN108986622A (zh) * 2018-08-16 2018-12-11 广州迈普再生医学科技股份有限公司 一种颅内血肿微创穿刺清除术培训装置及其制备方法
RU2712804C1 (ru) * 2018-08-29 2020-01-31 Жовнерчук Инна Юрьевна Способ коррекции функционального состояния человека в замкнутом пространстве
RU2789964C1 (ru) * 2022-04-01 2023-02-14 Александр Юрьевич Верховский Способ улучшения состояния кожи и подкожных тканей

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5228434A (en) * 1991-07-16 1993-07-20 Praxair Technology, Inc. Mixture for anesthesia
US5099834A (en) * 1991-07-16 1992-03-31 Union Carbide Industrial Gases Technology Corporation Method for anesthesia
US5357959A (en) * 1993-04-16 1994-10-25 Praxair Technology, Inc. Altered dipole moment magnetic resonance imaging method
EP0760819B1 (en) * 1994-05-24 2000-07-19 F. Hoffmann-La Roche Ag Tricyclic dicarbonyl derivatives
RU2072241C1 (ru) * 1995-09-20 1997-01-27 Панина Елена Владимировна Способ формирования дыхательной газовой смеси и аппарат для его осуществления
US5846556A (en) * 1996-06-14 1998-12-08 Brooks; Bradley S. Inhalant for reducing stress and method of use
IT1286058B1 (it) * 1996-10-29 1998-07-07 Siad Societa Italiana Acetilen Procedimento e apparecchiatura per la purificazione e recupero dello xeno e altri gas nobili in sistemi anestetici
DE19709704C2 (de) * 1997-03-10 1999-11-04 Michael Georgieff Verwendung einer flüssigen Präparation von Xenon zur intravenösen Verabreichung bei Einleitung und/oder Aufrechterhaltung der Anaesthesie
DE19823606C2 (de) * 1998-05-27 2002-02-28 Draeger Medical Ag Verwendung von Perfluorcarbone in einem Atemgasgemisch sowie die Vorrichtung
GB9917822D0 (en) * 1999-07-29 1999-09-29 Imperial College Nmda antagonist

Also Published As

Publication number Publication date
IL145177A0 (en) 2002-06-30
CN1359296A (zh) 2002-07-17
JP4954373B2 (ja) 2012-06-13
CA2367136A1 (en) 2000-09-14
CZ302864B6 (cs) 2011-12-21
HUP0201393A3 (en) 2002-10-28
SK12792001A3 (sk) 2002-07-02
AU3287500A (en) 2000-09-28
DE60004974T3 (de) 2012-06-28
HK1048073B (zh) 2005-06-03
EP1158992B2 (en) 2012-02-01
HK1048073A1 (en) 2003-03-21
CN1170544C (zh) 2004-10-13
DK1158992T3 (da) 2003-12-29
PT1158992E (pt) 2004-01-30
NO20014379D0 (no) 2001-09-10
MD2935B2 (en) 2005-12-31
IL145177A (en) 2006-10-31
KR20010108338A (ko) 2001-12-07
KR100674407B1 (ko) 2007-01-26
SI1158992T1 (en) 2004-02-29
ES2206202T3 (es) 2004-05-16
US8143317B2 (en) 2012-03-27
MD2935C2 (ro) 2006-08-31
EP1158992A1 (en) 2001-12-05
BR0010456A (pt) 2002-08-27
CA2367136C (en) 2008-05-13
DE19910986A1 (de) 2000-09-21
ATE248599T1 (de) 2003-09-15
AU757361B2 (en) 2003-02-20
BG105889A (bg) 2002-04-30
EE200100480A (et) 2002-12-16
NO20014379L (no) 2001-11-07
EP1158992B1 (en) 2003-09-03
ZA200107291B (en) 2003-02-26
AR022886A1 (es) 2002-09-04
US20030180375A1 (en) 2003-09-25
SK285111B6 (sk) 2006-06-01
DE60004974T2 (de) 2004-07-22
DE60004974D1 (de) 2003-10-09
RU2246949C2 (ru) 2005-02-27
MD20010349A (en) 2002-02-28
HUP0201393A2 (en) 2002-09-28
WO2000053192A1 (en) 2000-09-14
CZ20013234A3 (cs) 2002-06-12
PL202941B1 (pl) 2009-08-31
DE19910986C2 (de) 2001-06-07
US20070110821A1 (en) 2007-05-17
PL350618A1 (en) 2003-01-27
ES2206202T5 (es) 2012-05-22
JP2002538209A (ja) 2002-11-12
RS49756B (sr) 2008-04-04
US6559190B1 (en) 2003-05-06

Similar Documents

Publication Publication Date Title
YU65401A (sh) Primena ksenona ili smeša ksenonskog gasa za proizvodnju farmaceutskog preparata za lečenje neurointoksinacija
SG146648A1 (en) Pharmaceutical compositions for treating premature ejaculation by pulmonary inhalation
ATE381537T1 (de) Formanilid-derivative als beta2-adrenorezeptor- agonisten
WO2009082459A3 (en) Anti-aging composition containing resveratrol and method of administration
AP2088A (en) Phenethanolamine derivatives for treatment of respiratory diseases
MXPA04002405A (es) Derivados de fenetanolamina para tratamiento de enfermedades respiratorias.
HN2005000484A (es) Nuevas composiciones farmaceuticas para el tratamiento de trastornos hiperproliferativos
BR0316532A (pt) Composições farmacêuticas compreendendo, um composto de droga básico, respectivamente um ácido, um tensoativo e um ácido solúvel em água fisiologicamente tolerável, respectivamente, uma base
MX2010014234A (es) Compuestos pirazol 436.
UA84048C2 (ru) Производные сульфонамида для лечения заболеваний, способ их получения (варианты), фармацевтическая композиция на их основе
BRPI0500704A (pt) composições de tratamento pessoal reidratáveis
UA98804C2 (ru) Катехоламиновые производные и фармацевтическая композиция на их основе
MY144992A (en) Substituted 1,2,3,4-tetrahydroisoquinoline derivatives.
BRPI0416700A (pt) métodos para tratar obesidade, para alcançar perda de peso desejável, para evitar ganho de peso indesejável, e para facilitar a perda de peso em um indivìduo não sofrendo de depressão, métodos de manutenção de um peso estável e de redução do peso corporal em um indivìduo, composição farmacêutica, e, kit
AU2003298094A8 (en) Medicinal arylethanolamine compounds
TNSN07145A1 (fr) Derives de 2-amido-4-phenylthiazole, leur preparation et leur application en therapeutique
MX2010009623A (es) Derivados de 1-bencil-3-hidroximetilindazol novedosos y su uso en el tratamiento de enfermedades basadas en la expresion de mcp-1, cx3cr1 y p40.
DE602005021770D1 (de) Indol-1-yl-essigsäurederivate
EE200100491A (et) Tetrahüdropüraani derivaadid, nende saamine ja kasutamine ravimainetena ning neid sisaldav farmatseutiline kompositsioon
AR058121A1 (es) Enmascaramiento del sabor de los aceites esenciales usando un hidrocoloide
MX2009011543A (es) Metodo para la produccion de la 2,4'-dimetil-3-piperidino-propiofe nona (tolperisona), altamente pura, composiciones farmaceuticas que contienen la misma al igual que formulaciones de ingrediente activo que contienen la tolperisona.
TW200509907A (en) Indol-6-yl sulfonamide derivatives, their preparation and their use in medicaments
TW200626593A (en) Novel compounds
BR0208813A (pt) Composições contendo imidazotriazinona para a aplicação nasal
BR0008865A (pt) Composições contendo fluoreto estanhoso para o tratamento de dentes hipersensìveis